COVID-19 patients with severe disease exhibit increased monocyte counts with higher frequencies of classical monocytes, lower frequencies of intermediate/non-classical monocytes and elevated plasma levels of C-reactive protein (CRP) and serum TF in comparison to mild disease
doi: 10.1073/pnas.86.3.787 74 DriscollJBrownMGFinleyDMonacoJJ
A possible downside of FHE is that it can be computationally more expensive than other solutions
What This Means for Patients and Prescribers For individuals using peptide therapies under physician supervision: More pharmacy options : Physicians prescribing BPC-157, MOTS-C, or other affected peptides should find more pharmacies willing to fill the prescription Better quality control : Legitimate compounding pharmacies must meet sterility, potency, and endotoxin testing standards that gray-market sources typically don't Lower costs : Competition among compounding pharmacies typically drives prices down versus single-source gray-market procurement Telehealth access : Peptide-prescribing telehealth services that stopped offering these compounds due to pharmacy access problems may resume For those using peptides sourced from research chemical vendors: the gray market will likely shrink as legitimate compounding access improves
How BPC-157 Affects the Gut The scientific interest in BPC-157 primarily stems from its effects on gastrointestinal tissue in experimental models
This conjugation renders the previously fat-soluble toxins completely water-soluble, allowing them to be safely flushed out of the body via bile and urine
